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Abstract. de Jong SC, Stehouwer CDA, van den Berg
M, Geurts TW, Bouter LM, Rauwerda JA (Institute
for Cardiovascular Research; Division of Vascular
Surgery, Academisch Ziekenhuis; Department of
Internal Medicine, Academisch Ziekenhuis; and
Department of Epidemiology and Biostatistics, Vrije
Universiteit, Amsterdam, The Netherlands) Normo-
homocysteinaemia and vitamin-treated hyperhomo-
cysteinaemia are associated with similar risks of
cardiovascular events in patients with premature
peripheral arterial occlusive disease. A prospective
cohort study. J Intern Med 1999 246: 87±96.
Objectives. Mild hyperhomocysteinaemia (HHC),
fasting or after methionine loading, is associated
with an increased risk and severity of atherosclerotic
vascular disease. Post-methionine and fasting HHC
are responsive to treatment with vitamin B6 and folic
acid. We performed a prospective cohort study
amongst normohomocysteinaemic and vitamin-
treated (vitamin B6, 250 mg plus folic acid, 5 mg
daily) hyperhomocysteinaemic patients with pre-
mature peripheral arterial occlusive disease and
assessed the incidence of cardiovascular events.
Design. We studied 273 consecutive patients with
clinically manifest peripheral arterial occlusive
disease with onset before the age of 56, 79
(28.9%) of whom had postmethionine HHC. Fol-
low-up was obtained in 232 (85%) patients. At
baseline, 70 (30%) were hyperhomocysteinaemic
after methionine loading and started treatment with
vitamin B6 and folic acid; 162 (70%) were normo-
homocysteinaemic (reference group).
Results. During the follow-up period (median 20,
range 1±63 months), 48 (29.6%) and 23 (32.9%) of
the normo- and the hyperhomocysteinaemic pa-
tients, respectively, had a new cardiovascular event.
Most (75%) involved the peripheral arterial system.
The crude incidence rate for any cardiovascular
event was 0.16 (95% CI, 0.12±0.21) per person per
year in the normohomocysteinaemic and 0.16 (95%
CI, 0.09±0.22) per person per year in the hyperho-
mocysteinaemic group.
Multivariate Cox regression analyses showed that
higher plasma homocysteine levels were associated
with an increased risk of new cardiovascular events
in the normohomocysteinaemic patients (relative
risk [RR] per 1 mmol L21, 1.17 [CI, 1.05±1.30] for
fasting and 1.06 [CI, 1.01±1.12] for postmethionine
levels), but not in the hyperhomocysteinaemic
(vitamin-treated) patients. The adjusted RR for
new cardiovascular events in the hyper- as com-
pared to the normohomocysteinaemic patients was
0.76 (CI, 0.33±1.74).
Conclusions. These data are consistent with a
protective effect of treatment with vitamin B6 and
folic acid in patients with premature peripheral
arterial occlusive disease and postmethionine HHC.
Double-blind randomized trials are necessary to
confirm this.
Keywords: cardiovascular events, mild hyperhomo-
cysteinaemia, peripheral arterial occlusive disease,
prospective study, vitamin treatment.
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Introduction
Mild hyperhomocysteinaemia (HHC), fasting or after
methionine loading, is associated with an increased
risk of premature vascular disease [1±5]. Mild HHC
after methionine loading is found in a substantial
percentage of these patients, varying from 33% in
patients with peripheral to 15% in patients with
coronary arterial occlusive disease [6±9]. In addi-
tion, several studies have found relations between
the severity of atherosclerotic vascular disease and
homocysteine concentrations [10±12], including
postmethionine levels [10].
As in severe homocystinuria, treatment of HHC
with cofactors or cosubstrates of homocysteine
metabolism can lower homocysteine levels [7, 8,
13]. For example, postmethionine and fasting total
homocysteine (tHcy) levels were normalized after
treatment with 250 mg vitamin B6 plus 5 mg folic
acid in, respectively, 92 and 91% of vascular
patients with HHC [7]. Such treatment was asso-
ciated with a decrease in elevated plasma levels of
endothelium-derived proteins, which are thought to
reflect endothelial dysfunction [14]. These results
suggest that a reduction in tHcy levels is associated
with amelioration of endothelial dysfunction and by
this means may influence the course of athero-
thrombotic disease.
Patients with peripheral arterial occlusive disease
have an increased morbidity and mortality, which is
generally due to accompanying cardiovascular
disease [15, 16]. Furthermore, patients with even
slightly elevated tHcy levels are more likely to
demonstrate clinical progression of peripheral and
coronary artery disease than patients with normal
tHcy levels [17, 18]. It is not known whether
homocysteine-lowering treatment will influence
the clinical outcome of patients with peripheral
arterial occlusive disease who also have HHC. To
investigate this, we initially wished to perform a
placebo-controlled, randomized clinical trial of the
effects of vitamin B6 and folic acid on cardiovascular
outcomes, but this was not acceptable to the
hyperhomocysteinaemic patients, who indicated
that they strongly preferred treatment with B-
vitamins. We therefore chose to perform a prospec-
tive cohort study amongst normohomocysteinaemic
and vitamin-treated hyperhomocysteinaemic pa-
tients with premature peripheral arterial occlusive
disease.
Methods
Patients
In January 1991, we started a HHC screening
programme amongst consecutive patients who had
been directly referred by their general practioner to
the Department of Surgery, Division of Vascular
Surgery of the Academisch Ziekenhuis, Vrije Uni-
versiteit in Amsterdam, the Netherlands. All patients
with a history of clinically manifest peripheral
arterial occlusive disease with onset before the age
of 56 years underwent a methionine loading test
(see below). Peripheral arterial occlusive disease was
defined by the presence of intermittent claudication
confirmed by an ankle/brachial index ,0.9 at rest
and/or a decrease of .0.15 of the index after
treadmill exercise testing, or ischaemic rest pain
confirmed by a resting ankle pressure below
40 mmHg, gangrenous ulcers diagnosed by the
presence of a nonhealing ulcer confirmed by a
resting ankle pressure below 60 mmHg, or amputa-
tion for ischaemia.
From January, 1991, to June, 1995, we thus
screened 273 patients, of whom 35 (12.8%) had
fasting and 79 (28.9%) had postmethionine HHC.
Twenty-four patients had both fasting and post-
methionine HHC. All 79 patients with postmethio-
nine HHC were treated with vitamin B6 (250 mg)
plus folic acid (5 mg). All patients were then
followed routinely on a yearly basis or earlier when
clinically indicated. At the yearly visit, we specifi-
cally reviewed the occurrence of new cardiovascular
events and the progression of peripheral arterial
occlusive disease. In case of new symptoms or
progression of peripheral arterial occlusive disease,
noninvasive vascular tests were performed by
technicians not aware of other clinical and labora-
tory data. Seventeen patients were lost to follow-up
because they had moved to another area and could
not be contacted; four patients refused permission
for the prospective follow-up. These 21 patients were
excluded. Thus, 252 patients who had given written
informed consent were included. The study was
approved by the local ethics committee.
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Methionine loading test and laboratory analyses at
baseline
After an overnight fast, venous blood samples were
taken between 09.00 and 10.00 hours. Patients
were asked to refrain from smoking and from using
alcohol from 22.00 hours on the evening prior to
blood sampling. A second blood sample was
obtained 6 hours after an oral methionine load
(0.1 g kg21 body weight). Plasma samples were
stored at ± 30 8C until use. Plasma levels of tHcy
were determined within 1 week of blood sampling.
tHcy (free plus protein bound) concentrations were
measured by using tri-n-butylphosphine as the
reducing agent and ammonium 7-fluorobenzo-2-
oxa-1,3-diazole-4-sulphonate as the fluorochromo-
phore, followed by high-pressure liquid chromato-
graphy (HPLC) with fluorescence detection [19].
Reference values for fasting and postmethionine
tHcy levels in our laboratory are ,18 and
,54 mmol L21 in men, ,15 and ,51 mmol L21
in premenopausal women, and ,19 and
,69 mmol L21 in postmenopausal women [10].
These reference values were obtained from a group
of vitamin B6, B12, and folic acid-replete healthy
volunteers: mean age (SD) for men (n = 23) and
women (n = 41 pre- and n = 27 postmenopausal),
36.9 (5.7) and 42.3 (9.5), respectively. Patients
who, on the basis of these reference values, were
hyperhomocysteinaemic after methionine loading
(n = 79) started treatment with vitamin B6
(250 mg) plus folic acid (5 mg). Eleven patients
had fasting HHC (18.2 6 2.2 mmol L21) without
postmethionine HHC. They did not receive vitamin
treatment. After 12 weeks of treatment, the postload
tHcy concentration was within the reference range
in all patients.
At the time of the methionine loading test, we
recorded baseline data, i.e. age, body weight and
height, body mass index (the weight in kilograms
divided by the square of the height in metres),
menopausal status (postmenopause was defined as
absence of menstrual bleeds .1 years), current and
past smoking habits, use of medication (including
aspirin and oral anticoagulants), history of physi-
cian-diagnosed diabetes, hypertension and/or hy-
percholesterolaemia, and blood pressure (measured
after 15 min of supine rest). Diabetes and hyperten-
sion were defined according to WHO criteria;
hypercholesterolaemia as serum total cholesterol
.6.5 mmol L21 and/or the use of cholesterol-low-
ering medication. A detailed history was taken with
regard to angina pectoris, myocardial infarction,
transient ischaemic attack and stroke [10].
Just prior to the methionine loading test, venous
blood samples were taken for measurement of serum
lipids (total and high density lipoprotein [HDL]
cholesterol and triglycerides [enzymatically]). Low
density lipoprotein [LDL] cholesterol was calculated
by Friedewald's formula [20]. We also measured
serum levels of creatinine (modified JaffeÂ reaction),
vitamin B6 (measured as pyridoxal-5-phospate by
HPLC with fluorescence detection after precolumn
derivatization with semicarbazide; reference,
.17 nmol L21), vitamin B12 (radioassay, Becton
Dickinson, France; reference, .80 pmol L21), and
folate (radioassay, Becton Dickinson; reference,
.3.4 nmol L21).
Follow-up and identification of new cardiovascular
events
Each patient's duration of follow-up, in months, was
defined as the time between the performance of the
initial methionine loading test (baseline) and the
occurrence of the first new cardiovascular (coron-
ary, peripheral or cerebral arterial) event, or April
1st, 1996. If data from the hospital files were not
clear, the patient's general practitioner was con-
tacted for clarification. New coronary arterial
disease was defined as myocardial infarction and
newly diagnosed (WHO clinical definitions) or
progressive angina pectoris (reduction of exercise
tolerance estimated by a change in stage as defined
by the New York Heart Association, and/or unstable
angina, in all cases confirmed by exercise electro-
cardiographic stress testing and/or angiography).
New peripheral arterial disease was defined as new
intermittent claudication (defined as intermittent
claudication in the other limb from that in which
peripheral arterial occlusive disease had initially
been present, confirmed by an ankle/brachial index
,0.9 at rest and/or a decrease of .0.15 of the index
after treadmill exercise testing), or as progression of
peripheral arterial occlusive disease, defined as
progression of clinical symptoms: (i) new symptoms
of intermittent claudication in the same limb after
initially successful treatment by reconstructive
peripheral surgery or transluminal angioplasty
(PTA); (ii) a (subjective) decrease in the walking
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distance; (iii) occurrence of critical ischaemia,
defined by the occurrence of ischaemic rest pain or
gangrenous ulcers and confirmed by a resting ankle
pressure below 60 mmHg; (iv) acute arterial throm-
bosis. A diagnosis of progression of clinical symp-
toms was accepted only when confirmed by a
decrease in ankle/brachial index at rest of at least
0.15, and/or angiographically. New cerebral artery
disease was defined as transient ischaemic attack or
stroke (WHO clinical definitions). All diagnoses were
accepted only when corroborated by a written report
by a physician.
Of the 252 patients initially included, a further 20
were excluded from all analyses because data from
the hospital files were unclear or missing and no
additional information could be obtained from the
general practitioner. A total of 232 (85%) patients
were thus included; at baseline, 70 (30%) had
hyperhomocysteinaemia and 162 (70%) normoho-
mocysteinaemia after methionine loading (Fig. 1).
Compared to those included, the excluded group
(n = 41) did not differ significantly with regard to
the prevalence of the major cardiovascular risk
factors, i.e. male sex, cardiovascular history, smok-
ing, hypertension, hypercholesterolaemia, diabetes
mellitus, and hyperhomocysteinaemia (data not
shown).
Data analyses
Data were analysed using the statistical package
SPSS for Windows 6.1 (Chicago, Il, USA). Descrip-
tive data are given as mean (SD). Skewed data were
logarithmically transformed. Continuous variables
were compared by Student's t-test (for means) and
percentages by chi-square tests.
We assessed the incidence of cardiovascular
events in the follow-up period. We then calculated
crude incidence rates of cardiovascular events in the
entire group and separately for the patients with and
without postmethionine HHC. Our primary interest
was to analyse whether the presence of vitamin-
treated postmethionine HHC was related to the
incidence rate of cardiovascular events. Cox9 regres-
sion models were used for testing the association
between the incidence of cardiovascular events on
the one hand and possible prognostic baseline
covariates on the other, i.e. age, sex, menopausal
status, previous coronary and/or cerebral artery
disease, presence of hypercholesterolaemia, hyper-
tension and diabetes, current or past smoking and
number of pack years (pack years were calculated by
multiplying the number of cigarette packages
smoked per day by the number of years the patient
smoked), body mass index, use of aspirin or oral
anticoagulants, systolic and diastolic blood pressure,
serum lipids (total, HDL and LDL cholesterol, and
triglyceride), serum vitamin B6, B12 and folate,
serum creatinine, presence of fasting or postmethio-
nine HHC, and plasma tHcy concentrations (fasting,
postmethionine and delta [defined as the difference
between postmethionine and fasting tHcy level]). For
the patients with postmethionine HHC, we consid-
ered both their initial tHcy levels and those after
treatment. Covariates that had a P-value of ,0.2
when considered as a prognostic risk factor in
isolation were selected for multivariate Cox-regres-
sion analyses. Presence of HHC (yes/no) and plasma
tHcy level were never included together in the same
multivariate analysis.
All relative risks (RRs) are given with their 95%
confidence interval (CI) in parentheses and contrast
the risk in the presence versus the absence of the
relevant risk factor (e.g. presence versus absence of
hypertension or HHC) or are expressed per unit of
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162 patients without HHC
Fasting tHcy: 10.3 – 3.6
PML tHcy: 35.4– 9.9
70 patients with HHC
Fasting tHcy: 17.8– 12.7
PML tHcy: 74.2– 22.6
252 patients with
premature PAOD
21 patients lost
to follow-up
273 patients with
premature PAOD
20 patients excluded
because of insufficient
data
Fig. 1 Flow diagram of patient population.(PAOD, peripheral
arterial occlusive disease; PML, postmethionine loading; HHC,
hyperhomocysteinaemia).
that risk factor (e.g. 1 mmHg for diastolic blood
pressure and 1 mmol L21 for plasma tHcy level). All
testing was two-tailed with 0.05 as the level of
significance.
Results
Table 1 shows clinical characteristics of the 232
patients at baseline. Of the patients with postmethio-
nine HHC, 31.4% (22 out of 70) had a history of
coronary and/or cerebral artery disease, compared
to 25.5% (33 out of 162) of the normohomocystei-
naemic patients (P = 0.08). After treatment of the
patients with postmethionine HHC with vitamin B6
plus folic acid, their fasting tHcy levels were lower
than the fasting levels in the patient group without
HHC (P = 0.01). However, the increase in tHcy
levels (delta) after treatment, although within the
reference range, remained higher in the patients
with postmethionine HHC (P = 0.01).
During the follow-up period (median 20; range 1±
63 months), 48 (29.6%) and 23 (32.9%) of the
patients with postmethionine normo- and hyperho-
mocysteinaemia, respectively, had a new cardiovas-
R I S K S O F C A R D I O V A S C U L A R E V E N T S 9 1
# 1999 Blackwell Science Ltd Journal of Internal Medicine 246: 87±96
Table 1 Baseline clinical and laboratory characteristics of 232 patients with premature peripheral arterial occlusive disease
patients
without HHC
(162)
patients
with HHCa
(70) P-value
n (%), M/F 90/72(55.6/44.4) 31/39 (44.3/55.7) 0.11
Follow-up (months) 21.8  12.9 24.7  13.0 0.07
Age, y 45.6  6.8 45.8  6.8 0.88
Postmenopausal, n (%) 28(17.3) 12(17.1) 0.48
Use of aspirin and/or oral anticoagulants 74(45.7) 26(37.1) 0.25
Cardiovascular history, n (%)b 33(25.5) 22(31.4) 0.08
Body mass index (kg m22) 24.9  4.2 25.4  4.5 0.51
Current smokers, n (%) 125(77.2) 59(84.3) 0.15
Current or past smokers, n (%) 145(89.5) 63(90) 0.29
Pack yearsc 27.6  15.1 27.2  14.4 0.79
Hypertension, n (%) 40(24.7) 21(30.0) 0.40
Blood pressure (mm Hg)
Systolic 142.4  19.0 140.6  18.5 0.71
Diastolic 86.3  11.4 85.1  9.0 0.29
Hypercholesterolaemia, n (%) 44(27.2) 32(45.7) 0.006
Total cholesterol (mmol L21) 6.1  1.3 6.0  1.1 0.85
LDL cholesterol (mmol L21)d 4.2  1.2 4.0  1.0 0.53
HDL cholesterol (mmol L21) 1.1  0.4 1.1  0.3 0.96
Triglyceride (mmol L21) 1.8  1.2 2.1  1.2 0.35
Diabetes mellitus, n (%) 14(8.6) 2(2.9) 0.11
Baseline plasma tHcy (mmol L21)
Fasting 10.3  3.6 17.8  12.7 0.001
Post-methionine 35.4  9.9 74.2  22.6 not tested
Deltae 25.9  8.3 56.6  20.8 0.001
After treatmentf
Fasting 8.2  2.2 0.001
Post-methionine 36.3  9.4 0.41
Delta 28.5  8.6 0.01
Folate (nmol L21) 9.7  5.6 8.6  4.9 0.14
Vitamin B6 (nmol L
21) 30.8  33.7 27.5  34.6 0.20
Vitamin B12 (pmol L
21) 258.4  87.2 261.8  93.2 0.94
Creatinine (mmol L21) 84.9  21.5 85.8  21.1 0.73
Data are given as number (n) with percentages in parentheses or as mean with SD. HHC, hyperhomocysteinaemia after methionine loading.
tHcy, total homocysteine. aThese patients subsequently received homocysteine-lowering treatment with folic acid and vitamin B6 (see
Methods). bCardiovascular history was defined as a history of angina pectoris, myocardial infarction, transient ischaemic attack and/or
stroke. cPack years were calculated by multiplying the number of cigarette packages smoked per day by the number of years the patient
smoked. dCalculated by Friedewald's formula. eDelta indicates the difference between postmethionine and fasting tHcy level. fFasting and
postmethionine tHcy levels after treatment were tested against fasting and postmethionine tHcy levels of the patients without HHC.
cular event (Table 2). The crude incidence rate for
any cardiovascular event was 0.16 (CI, 0.12±0.20)
per person per year in the entire group, 0.16 (CI,
0.12±0.21) per person per year in those with
postmethionine normohomocysteinaemia and 0.16
(CI, 0.09±0.22) per person per year in those with
postmethionine HHC. The crude RR for the occur-
rence of cardiovascular events for the hyper-
compared to the normohomocysteinaemic patients
was 0.96 (CI, 0.59±1.55). The incidence rates of
peripheral, coronary or cerebral arterial events did
not differ between the groups. Figure 2 shows
Kaplan±Meier curves in the normo- and hyperho-
mocysteinaemic patients groups separately.
Table 3 gives the results of univariate and multi-
variate Cox-regression analyses. All other risk
factors tested (see Statistical analysis) had a P-value
.0.2 when considered univariately (data not
shown). In multivariate analysis in the entire group
of patients, fasting tHcy and triglyceride levels
showed significant associations with the incidence
of new cardiovascular events. After exclusion of the
35 patients with fasting HHC, the RR for fasting
tHcy levels was 1.12 (CI, 0.98±1.27; P = 0.09). In
the patients with normal postmethionine tHcy levels,
multivariate analyses showed significant associa-
tions between the incidence of new cardiovascular
events and triglyceride levels and both fasting and
postmethionine tHcy levels. After exclusion of the
11 patients with normal postmethionine but ele-
vated fasting tHcy levels, RRs for fasting and
postmethionine tHcy levels were, respectively, 1.04
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Table 2 Incidence rates of new cardiovascular events in 232 patients with premature peripheral arterial occlusive disease
patients without
HHC
(n = 162)
patients with
HHCa
(n = 70)
Cardiovascular events (n) 0.16 (48) 0.16 (23)b
Peripheral arterial occlusive events (n) 0.13 (38) 0.11 (16)
New intermittent claudication (n) 0.014 (4) 0.007 (1)
Progression of peripheral arterial
occlusive disease (n)
0.12 (34)c 0.10 (15)c
Coronary arterial occlusive events (n) 0.024 (7) 0.04 (6)
Angina pectoris or progression of angina pectoris (n) 0.02 (5)d 0.03 (5)
Myocardial infarction (n) 0.007 (2)e 0.007 (1)
Cerebral arterial occlusive events (n) 0.01 (3) 0.01 (2)
Transient ischaemic attack (n) 0.007 (2) 0.01 (2)
Stroke (n) 0.003 (1) 0
Deathf (n) 0.007 (2)g 0.01 (2)
Incidence rates are expressed as events per person per year. HHC, hyperhomocysteinaemia after methionine loading. n, number of patients.
aThese patients received homocysteine-lowering treatment with folic acid and vitamin B6 (see Methods).
bIn the hyperhomocysteinaemic
group, one patient developed both claudication and angina pectoris at the same time. In Cox-regression analyses this was considered as one
cardiovascular event. cOf the patients without HHC, 22 had new symptoms after initially successful treatment; 7 had a decrease of walking
distance; 4 developed critical ischaemia; and 1 had arterial thrombosis. Amongst the patients with HHC, these numbers were 7, 2, 5, and 1
(see Methods for definitions of these categories). d2 patients had progressive angina.
eone patient died < 1 month after a myocardial infarction. fThree additional patients died; two hyperhomocysteinaemic patients shortly
but > 1 month after a new cardiovascular event and one of carcinomag.
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Fig. 2 Kaplan±Meier curves of the occurrence of new
cardiovascular events in patients with premature peripheral
arterial occlusive disease with normohomocysteinaemia (solid line)
and hyperhomocysteinaemia (dashed line) after methionine
loading.
(CI, 0.88±1.24; P = 0.61) and 1.05 (CI, 0.98±1.15;
P = 0.16). When both fasting and postmethionine
tHcy were included in the original model, only the
association with fasting tHcy remained significant
(RR, 1.17; CI, 1.05±1.31). If we then forced
postmethionine tHcy into the model, the RR was
1.02 (CI, 0.95±1.08; P = 0.63) for postmethionine
and 1.14 (CI, 0.98±1.33; P = 0.08) for fasting tHcy.
In the patients with postmethionine HHC, there were
no significant associations between new cardiovas-
cular events and baseline variables or with post-
treatment fasting (adjusted RR, 1.01; CI, 0.76±1.33;
P = 0.94) or postmethionine tHcy levels (adjusted
RR, 1.01; CI, 0.95±1.07; P = 0.73).
The adjusted RR for the occurrence of cardiovas-
cular events for the patients with HHC, compared to
those with normohomocysteinaemia after methio-
nine loading, was 0.76 (CI, 0.33±1.74).
During the follow-up period, newly diagnosed
hypertension and hypercholesterolaemia occurred
in, respectively, 2.4 and 2.4% of the hyperhomo-
cysteinaemic patients compared to 5.1 and 6.3%
(respectively) of the normohomocysteinaemic pa-
tients. In addition, 11.9% of the hyperhomocystei-
naemic patients stopped smoking and 4.8% started
smoking. In the normohomocysteinaemic patients,
21% stopped smoking and 1.3% started smoking.
These changes and the changes in treatment of
patients with hypercholesterolaemia and/or hyper-
tension did not differ significantly between the
groups. Multivitamin use at baseline or during
follow-up was infrequent (2 patients).
Discussion
Our study is the first to prospectively investigate the
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Table 3 Cox-regression analysis: risk factors for new cardiovascular events in patients with premature peripheral arterial occlusive diseasea
All patients
(n = 232)
Relative risk P-value
Patients without HHC
(n = 162)
Relative risk P-value
Patients with HHCb
(n = 70)
Relative risk P-value
Univariate analyses
Male sex 2.05 (1.25±3.34) 0.004 1.95 (1.06±3.58) 0.03 2.17 (0.93±5.03) 0.07
Cardiovascular history (yes/no)c 1.66 (0.98±2.80) 0.06 ± ± 2.32 (0.94±5.72) 0.07
Body mass index (per 1 kg m22) ± ± 0.94 (0.86±1.03) 0.19 ± ±
Pack years (per 1)d 1.01 (0.996±1.03) 0.15 ± ± 1.02 (0.99±1.05) 0.19
Diastolic blood pressure (per 1 mmHg) 0.98 (0.95±1.01) 0.17 0.97 (0.94±1.01) 0.11 ± ±
Hypercholesterolaemia (yes/no) ± ± 1.86 (1.02±3.40) 0.04 ± ±
Total cholesterol (per 1 mmol L21) 1.18 (0.95±1.48) 0.14 ± ± 1.47 (0.83±2.60) 0.19
HDL cholesterol (per 1 mmol L21) 0.51(0.21±1.26) 0.15 0.46 (0.17±1.26) 0.13 ± ±
Triglyceride (per 1 mmol L21) 1.30 (1.04±1.64) 0.02 1.48 (1.15±1.90) 0.002 ± ±
Fasting HHC (yes/no) ± ± 3.20 (1.24±8.23) 0.02 ± ±
tHcy levels (per 1 mmol L21)e
Fasting 1.13 (1.06±1.21) 0.0003 1.16 (1.08±1.26) 0.0002 ± ±
Post-methionine 1.02 (0.998±1.05) 0.08 1.04 (1.01±1.07) 0.02 ± ±
Delta ± ± 1.02 (0.99±1.06) 0.17 ± ±
Vitamin B6 (per 1 nmol L
21) 0.98 (0.96±0.99) 0.01 0.98 (0.96±1.002)
Multivariate analysesf
0.08 0.97 (0.93±1.004) 0.08
Triglyceride (per 1 mmol L21) 1.58 (1.13±2.20) 0.002 1.50 (1.07±2.11) 0.02 ± ±
tHcy levels (per 1 mmol L21)e
Fasting 1.20 (1.09±1.34) 0.0004 1.17 (1.05±1.30) 0.006 ± ±
Post-methionine ± ± 1.06 (1.01±1.12) 0.02 ± ±
HHC, hyperhomocysteinaemia after methionine loading. tHcy, total homocysteine levels. Relative risks (95% confidence intervals) are
shown. For the univariate analyses, all RRs with P < 0.2 are shown. For the multivariate analyses, all RRs with P < 0.05 are shown.
aFollow-up was (median and range) 20 (1±63) months. bThese patients received homocysteine-lowering treatment with folic acid and
vitamin B6 (see Methods).
cCardiovascular history was defined as a history of angina pectoris, myocardial infarction, transient ischaemic
attack and/or stroke. dPack years were calculated by multiplying the number of cigarette packages smoked per day by the number of years
the patient smoked. ePlasma tHcy levels of the hyperhomocysteinaemic patients are those after treatment (see Methods). fAdjusted for all
variables with univariate P < 0.2 as shown in the upper part of the table.
effects of homocysteine-lowering treatment with
vitamin B6 (250 mg) plus folic acid (5 mg) on the
natural course of atherothrombotic disease in
patients with premature peripheral arterial occlusive
disease and postmethionine HHC. Our data show
that, during an average follow-up of 2 years, the
cardiovascular prognosis of patients with post-
methionine HHC treated with vitamin B6 and folic
acid was similar to or, in the adjusted analysis,
slightly better than that of (untreated) patients with
normal postmethionine tHcy levels.
Our study population consisted of consecutive
patients with premature peripheral arterial occlusive
disease referred to a clinical vascular surgery
service. In agreement with previous experience, we
found a high prevalence of postmethionine and
fasting HHC, as well as other cardiovascular risk
factors [1, 6±9, 21, 22]. In the whole group, the
crude incidence rate for any cardiovascular event
after a mean follow-up period of about 2 years was
0.16 per person per year. About 75% of these events
involved progression of peripheral arterial occlusive
disease; the remaining 25% consisted of coronary
and cerebral artery disease (Table 2). Three studies
in elderly patients (mean age 61±67 years versus 46
in the present study) found rates of coronary and
cerebral artery disease that were similar to ours, and
rates of progression of peripheral artery disease that
varied from being much lower than in the present
study [16, 23] to being comparable [17]. Taken
together, these data suggest that our study popula-
tion is representative of patients with premature
peripheral arterial occlusive disease.
Only two prospective studies have investigated
clinical outcomes of untreated hyperhomocysteinae-
mic vascular patients. These studies showed that
hyperhomocysteinaemic patients, compared to those
with normohomocysteinaemia, had a two- to four-
fold incidence of cardiovascular morbidity and
mortality [17, 18]. Our data show that the cardio-
vascular prognosis of patients with premature
peripheral arterial disease who have HHC after
methionine loading and are treated with vitamin B6
and folic acid is similar to, or, if anything, slightly
better than, that of comparable patients who are
normohomocysteinaemic after methionine loading.
We suggest that these findings, taken together, are
consistent with a protective effect of treatment with
vitamin B6 and folic acid.
In patients with vascular disease not treated with
homocysteine-lowering agents, even slightly ele-
vated tHcy levels have been found to be associated
with more severe atherosclerosis [10±12]. In agree-
ment with these studies [10±12], we found that the
hyperhomocysteinaemic, when compared to the
normohomocysteinaemic, patients had a higher
prevalence of coronary and/or cerebral artery
disease at baseline (Table 1) and that higher tHcy
levels were positively and significantly related to the
incidence of new cardiovascular events (Table 3). It
is noteworthy that the latter relation was essentially
confined to the normohomocysteinaemic patients,
because the absence of such a relation amongst the
vitamin-treated hyperhomocysteinaemic patients is
again consistent with a protective effect of vitamin
treatment. In addition, the association of tHcy levels
with the incidence of cardiovascular events in the
normohomocysteinaemic patients is in line with
recent data indicating that such a relationship
extends well within the range of homocysteine
levels previously considered normal [18]. Finally,
our data are consistent with data showing that
treatment with vitamin B6, when accompanied by a
decrease in tHcy levels, is associated with a
decreased incidence of thromboembolic disease
amongst patients with cystathionine-b-synthase
deficiency, i.e. with severe HHC [13, 24].
The most important limitation of our study was
that the vitamin treatment was nonrandomized and
not blinded. Therefore, alternative explanations for
our findings must be carefully considered. First,
patients with HHC may have had less cardiovascular
risk factors at baseline than patients without HHC.
This is not supported by the data shown in Table 1,
but we cannot exclude that unmeasured other risk
factors differed between the groups. Secondly,
assessment of new cardiovascular events might
have differed between the groups. However, we
stress that we used objective criteria, so this appears
unlikely. Thirdly, treatment of cardiovascular risk
factors such as hypertension and hypercholester-
olaemia might have been more intensive in the
hyperhomocysteinaemic group. We found no evi-
dence that this was the case. We did not assess
whether the patients prescribed vitamin treatment
actually took their vitamins. If they did not,
however, one would expect an increased incidence
of cardiovascular events in the patients with
postmethionine HHC, which was not what we
found. Finally, and most important, the patients
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with postmethionine HHC might have changed their
life-style in such a way that it decreased their
cardiovascular risk. Although the data on, for
example, changes in smoking habits during the
follow-up period clearly do not support this notion,
we cannot fully exclude it.
It should be emphasized that the present study
was performed in patients with premature periph-
eral arterial occlusive disease, who had a high rate
of cardiovascular complications. Therefore, it is not
clear whether our results can be generalized to other
patient groups. In addition, we cannot exclude that
the favourable effects observed in the vitamin-
treated group are due to effects of vitamin B6 and/
or folic acid other than homocysteine lowering [25±
27]. Our study was too small to address, with
sufficient precision, the question whether the fasting
or the postmethionine tHcy level is the strongest
predictor of an adverse outcome.
In summary, our data support the hypothesis that
homocysteine-lowering treatment with vitamin B6
plus folic acid can reduce the rapid progression of
vascular disease in patients with premature periph-
eral arterial occlusive disease and postmethionine
HHC. Randomized controlled trials are necessary to
definitively confirm the effects of folic acid plus
vitamin B6 on cardiovascular disease progression in
hyperhomocysteinaemic patients with vascular dis-
ease and to determine the optimal treatment regi-
men. Such trials should focus on both fasting and
postmethionine tHcy levels [2, 10] and, in view of
recent data showing a continuous relation between
tHcy levels and risk of vascular disease [2, 18],
should probably use definitions of HHC with lower
cut-offs, i.e. less conservative than those we used.
Until such studies have been performed, we suggest
that it is reasonable to consider treatment with folic
acid and vitamin B6 in patients with premature
peripheral arterial occlusive disease who also have
postmethionine HHC.
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